1.6M+ Patient Diagnoses Enabled per week
Every moment matters when facing a cancer diagnosis. Leica Biosystems empowers healthcare professionals to quickly and reliably deliver accurate diagnoses, transforming anxiety into answers for millions of people worldwide.
~1700 Total Patents Worldwide
Our innovation is fueled by R&D investment and proven by a robust patent portfolio. We envision a world where comprehensive insights enrich cancer diagnoses and offer reassurance to all patients.
3000+ Associates Worldwide
Continuous improvement drives our global experts. We know real breakthroughs come from inclusive teams that think big, learn from diverse perspectives, and focus on outcomes that matter.
Dr. Darren Treanor, MB, BSc (Computing), PhD, FRCPath
Director, National Pathology Imaging Co-operative, UK
Consultant Histopathologist, Leeds Teaching Hospitals NHS Trust, UK
Honorary Clinical Professor, University of Leeds, UK
Adjunct Professor in Digital Pathology, Linköping University, Sweden
“The Leica Biosystems team understand that standardisation and interoperability are vital for the adoption of digital pathology and development of artificial intelligence. We value their methodical and practical approach, helping pathology to become increasingly digital and advancing our work at the UK National Pathology Imaging Co-operative program.”
Dr. Sylvia L. Asa, MD, PhD
Consultant in Endocrine Pathology, University Hospitals Cleveland Medical Center
"Leica Biosystems products are reliable and high quality, and the company is realistic about what's required to transform traditional pathology to a digital, connected practice. I know I can count on them and trust they will be there to support me now and well into the future."
Dr. Eric Peltier
Président Directeur Général - PRAXEA-DIAGNOSTICS
Thanks to our partnership with Leica, we have access to instruments of the highest caliber. The whole approach is about the quality, traceability, and connectivity…It's a base to work on innovation and development relying on the know-how of the pathologist. We also want to develop other technologies associated with this basis. So, it can be digital pathology technologies based on artificial intelligence.
Professor Koichi Ohshima PhD MD
Department of Pathology, School of Medicine, Kurume University
"Thank you for the fine connective system from Leica Biosystems, the systems well match the pathology works and studies at Kurume University. Recently we have tried to do case studies with hematologists and hematopathologists from over 20 hospitals and universities, using the virtual slide systems. The virtual slides work well in the web meetings, allowing good communication with the hematologists and hematopathologists. We are looking forward to collaborating with Leica Biosystems with Digital Pathology in the future."
News & Promotions
Explore Our Fully Automated BOND IHC & ISH Stainer Solutions
Workflow is key topic for each laboratory
Given each laboratory is unique, and each day is full of surprises, it is important to find the right stainer to fit your laboratory needs. Each BOND stainer provides a differentiated workflow solution thereby enabling your laboratory needs.
For In Vitro Diagnostic Use
Leica Biosystems Acquires Cell IDx
Cell IDx, a Leica Biosystems Company: United In Creating Next-Generation Tissue-Based Diagnostics
Cell IDx and Leica Biosystems combine expertise to deliver high-throughput UltraPlex Fluorescent and Chromogenic multiplex biomarker tissue profiling
Fully Automated Novocastra IHC and Kreatech FISH probes for BOND
How to do more with one stainer
Behind every sample in your laboratory there is patient who needs answers. They rely on the quality of results for an accurate diagnosis. They depend on your efficiency to avoid delays. Leica Biosystems delivers a range of solutions to meet your laboratory needs.